未公開のデータはメタ分析に含められるべきか? 現在の有罪判決と論争
1Department of Medicine, McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada.
JAMA
|June 2, 1993
まとめ
ほとんどのメタアナリシスには未公開のデータが含まれていませんが,研究者は,包括的な概要のためにそれを含めなければならないと考えています. 公開されていないデータを含めると,利用可能な情報のより有効な合成が保証されます.
科学分野:
- 医学研究方法論 医学研究方法論
- 根拠に基づいた医学は,エビデンスに基づいた医療です.
- 科学文献の合成科学文献の合成
背景:
- メタアナリシスは,研究成果を統合する上で極めて重要です.
- 未公開のデータをメタ分析に含めることは,議論の余地のある話題です.
- 未発表データの研究合成への影響を評価することが重要です.
研究 の 目的:
- メタアナリシスに未公開データの含有範囲を決定する.
- 編集者,メタアナリスト,および未公開データを含む方法論者の意見を評価する.
- 出版バイアスとデータアクセシビリティに対する態度を探求する.
主な方法:
- 1989年1月から1991年2月に出版されたメタ解析の文献レビュー.
- メタ分析の著者,方法論の著者,雑誌の編集者の横断的な調査.
- 未公開のデータ検索,取得,メタ分析への含有に関する評価.
主要な成果:
- レビューされたメタアナリシスの30.7%は,未公開のデータを含んでいた.
- メタアナリストと方法論家の過半数 (77.7%) は,未公開資料を含むことを支持した.
- メタアナリストと方法論家の大半 (86.4%) は,以前の概要の含有は,オリジナルの出版物に影響すべきではないと考えた.
結論:
- メタアナリシスに未発表データを含めることは論争の的だが,ほとんどのメタアナリシストが支持している.
- 未公開データの体系的な排除は,包括的なエビデンス・シンセシスを妨げる可能性があります.
- 公開されたデータと非公開されたデータの厳密な方法論的評価は,有効なメタアナリシスには不可欠です.
関連する概念動画
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:24Gonadal and Placental Hormones
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair growth — and...
01:12Analysis of Population Pharmacokinetic Data
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...